DK3303379T3 - Tigit-bindende midler og anvendelser deraf - Google Patents

Tigit-bindende midler og anvendelser deraf Download PDF

Info

Publication number
DK3303379T3
DK3303379T3 DK16800775.5T DK16800775T DK3303379T3 DK 3303379 T3 DK3303379 T3 DK 3303379T3 DK 16800775 T DK16800775 T DK 16800775T DK 3303379 T3 DK3303379 T3 DK 3303379T3
Authority
DK
Denmark
Prior art keywords
binding materials
tigit binding
tigit
materials
binding
Prior art date
Application number
DK16800775.5T
Other languages
English (en)
Inventor
Austin Gurney
Ming-Hong Xie
Original Assignee
Mereo Biopharma 5 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 5 Inc filed Critical Mereo Biopharma 5 Inc
Application granted granted Critical
Publication of DK3303379T3 publication Critical patent/DK3303379T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK16800775.5T 2015-05-28 2016-05-27 Tigit-bindende midler og anvendelser deraf DK3303379T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562167582P 2015-05-28 2015-05-28
US201562205279P 2015-08-14 2015-08-14
US201662313487P 2016-03-25 2016-03-25
PCT/US2016/034549 WO2016191643A2 (en) 2015-05-28 2016-05-27 Tigit-binding agents and uses thereof

Publications (1)

Publication Number Publication Date
DK3303379T3 true DK3303379T3 (da) 2021-12-06

Family

ID=57393726

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16800775.5T DK3303379T3 (da) 2015-05-28 2016-05-27 Tigit-bindende midler og anvendelser deraf

Country Status (29)

Country Link
US (2) US10112997B2 (da)
EP (2) EP3303379B1 (da)
JP (2) JP6875295B2 (da)
KR (1) KR20180014050A (da)
CN (2) CN109071620B (da)
AU (1) AU2016267577B2 (da)
BR (1) BR112017025529A2 (da)
CA (1) CA2987607A1 (da)
CL (1) CL2017003021A1 (da)
CO (1) CO2017012342A2 (da)
CY (1) CY1125260T1 (da)
DK (1) DK3303379T3 (da)
EC (1) ECSP17083779A (da)
ES (1) ES2902150T3 (da)
HR (1) HRP20211948T1 (da)
HU (1) HUE057087T2 (da)
IL (1) IL255577B (da)
LT (1) LT3303379T (da)
MA (1) MA42622B1 (da)
MD (1) MD3303379T2 (da)
MX (1) MX2017014955A (da)
NZ (1) NZ738008A (da)
PL (1) PL3303379T3 (da)
PT (1) PT3303379T (da)
RS (1) RS62815B1 (da)
SA (1) SA517390370B1 (da)
SI (1) SI3303379T1 (da)
TW (1) TWI715587B (da)
WO (1) WO2016191643A2 (da)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104655854A (zh) 2008-04-09 2015-05-27 健泰科生物技术公司 用于免疫相关疾病的治疗的新组合物和方法
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
UA122395C2 (uk) 2014-08-19 2020-11-10 Мерк Шарп Енд Доум Корп. Антитіло проти tigit
KR102644115B1 (ko) 2014-12-23 2024-03-05 브리스톨-마이어스 스큅 컴퍼니 Tigit에 대한 항체
EP3259597B1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment
US10227408B2 (en) 2015-02-19 2019-03-12 Compugen Ltd. Anti-PVRIG antibodies and methods of use
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
WO2017037707A1 (en) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
RU2729379C1 (ru) 2015-10-01 2020-08-06 Потенза Терапевтикс, Инк. Анти-tigit антигенсвязывающие белки и способы их применения
IL261188B (en) * 2016-03-04 2022-08-01 Jn Biosciences Llc An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
EP3432927A4 (en) 2016-03-24 2019-11-20 Gensun Biopharma Inc. TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
SG11201808783XA (en) 2016-04-15 2018-11-29 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
TWI760352B (zh) 2016-08-09 2022-04-11 英商克馬伯有限公司 抗ｉｃｏｓ抗體
AU2017313405A1 (en) * 2016-08-17 2019-02-28 Compugen Ltd. Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
NZ753515A (en) 2016-11-30 2022-02-25 Oncomed Pharm Inc Methods for treatment of cancer comprising tigit-binding agents
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
EP3565839A4 (en) * 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
EP3565889A4 (en) * 2017-01-06 2020-12-16 Nantkwest, Inc. CD96 / TIGIT GENETICALLY MODIFIED REDUCED EXPRESSION NK-92 CELLS
JP2020510422A (ja) * 2017-02-28 2020-04-09 シアトル ジェネティックス， インコーポレイテッド 抗ｔｉｇｉｔ抗体
NZ756395A (en) 2017-03-16 2024-01-26 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
JOP20190203A1 (ar) * 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018187191A1 (en) 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions and methods for the treatment of cancer
JP2020517699A (ja) 2017-04-26 2020-06-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ジスルフィド結合の還元を最小限にする抗体製造法
HUE062927T2 (hu) * 2017-05-01 2023-12-28 Agenus Inc Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
AU2018276140A1 (en) 2017-06-01 2019-12-19 Compugen Ltd. Triple combination antibody therapies
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US11161897B2 (en) 2017-07-17 2021-11-02 Janssen Biotech, Inc. Antigen binding regions against fibronectin type III domains and methods of using the same
KR20200100589A (ko) 2017-07-27 2020-08-26 아이테오스 테라퓨틱스 에스에이 항-tigit 항체
WO2019023504A1 (en) 2017-07-27 2019-01-31 Iteos Therapeutics Sa ANTI-TIGIT ANTIBODIES
BE1025333B1 (fr) * 2017-07-27 2019-01-23 Iteos Therapeutics S.A. Anticorps anti-tigit
JP7317272B2 (ja) * 2017-09-29 2023-07-31 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2019079520A2 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF
WO2019079777A1 (en) * 2017-10-20 2019-04-25 Fred Hutchinson Cancer Research Center COMPOSITIONS AND METHODS FOR TIGIT AND / OR CD112R TARGETING IMMUNOTHERAPY OR COMPRISING THE OVEREXPRESSION OF CD226
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
SG11202005595YA (en) * 2018-01-15 2020-07-29 Nanjing Legend Biotech Co Ltd Antibodies and variants thereof against tigit
JP2021521784A (ja) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
TW202011984A (zh) 2018-04-18 2020-04-01 美商山可爾股份有限公司 IL-15/IL-15Rα異二聚體Fc融合蛋白及其用途
US11001635B2 (en) 2018-06-29 2021-05-11 Gensun Biopharma Inc. Antitumor antagonists
TWI754157B (zh) 2018-07-25 2022-02-01 大陸商信達生物製藥（蘇州）有限公司 抗ｔｉｇｉｔ抗體及其用途
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
CN113195523A (zh) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12异源二聚体Fc融合蛋白
MA53862A (fr) 2018-10-12 2022-01-19 Xencor Inc Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
US20220306733A1 (en) * 2019-01-07 2022-09-29 iTeos Belgium SA Anti-tigit antibodies
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US20220146500A1 (en) * 2019-02-27 2022-05-12 Yale University Compositions and methods for enhancing mucosal immunity
US20220135682A1 (en) 2019-03-11 2022-05-05 Jounce Therapeutics, Inc. Anti-ICOS Antibodies for the Treatment of Cancer
CN109734806B (zh) * 2019-03-15 2022-07-01 安徽安科生物工程（集团）股份有限公司 一种全人源抗huTIGIT单克隆抗体及其应用
TWI760751B (zh) 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
WO2020251187A1 (ko) * 2019-06-13 2020-12-17 주식회사 녹십자 Tigit에 대한 항체 및 이의 용도
AU2020298324A1 (en) * 2019-06-21 2022-01-27 Single Cell Technology, Inc. Anti-TIGIT antibodies
CN114007646A (zh) * 2019-06-25 2022-02-01 南京金斯瑞生物科技有限公司 抗cd47/抗tigit双特异抗体及其制备方法和应用
CN114340735A (zh) 2019-06-28 2022-04-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN110669139A (zh) * 2019-09-18 2020-01-10 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
TWI764291B (zh) * 2019-09-24 2022-05-11 財團法人工業技術研究院 抗tigit抗體及使用方法
WO2021062332A1 (en) * 2019-09-27 2021-04-01 Icahn School Of Medicine At Mount Sinai Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US20220378909A1 (en) 2019-11-05 2022-12-01 Jounce Therapeutics, Inc. Methods of Treating Cancer with Anti-PD-1 Antibodies
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
CN112409450B (zh) * 2020-03-29 2023-01-24 郑州大学 TIGIT-IgV的亲和剂及其应用
CN113563470B (zh) 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
US20230258645A1 (en) 2020-05-07 2023-08-17 Institut Curie Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
WO2021247591A1 (en) 2020-06-02 2021-12-09 Arcus Biosciences, Inc. Antibodies to tigit
WO2021258337A1 (en) * 2020-06-24 2021-12-30 Huahui Health Ltd. Human monoclonal antibodies against tigit for immune related diseases
IL298993A (en) 2020-07-07 2023-02-01 BioNTech SE Therapeutic RNA for HPV positive cancer
CN111763660A (zh) * 2020-08-07 2020-10-13 南京大学 一种重组溶瘤痘苗病毒及其制备方法和应用
CN115708865A (zh) * 2020-08-25 2023-02-24 沣潮医药科技（上海）有限公司 Tigit免疫粘附素在制备调节血管生成产品中的应用
MX2023004808A (es) * 2020-10-26 2023-05-10 Akeso Biopharma Inc Anticuerpo anti-tigit y composicion farmaceutica y uso del mismo.
MX2023004941A (es) 2020-11-08 2023-07-12 Seagen Inc Conjugado de anticuerpo y fármaco para terapia de combinación con inhibidor de células inmunitarias.
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
TW202222345A (zh) * 2020-11-26 2022-06-16 大陸商信達生物製藥（蘇州）有限公司 包含抗ｔｉｇｉｔ／ｐｄ－１雙特異性抗體的製劑及其製備方法和用途
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
TW202304999A (zh) 2021-04-09 2023-02-01 美商思進公司 以抗tigit抗體治療癌症之方法
AU2022253351A1 (en) 2021-04-09 2023-10-12 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
EP4317184A1 (en) 2021-04-22 2024-02-07 Guangdong Fapon Biopharma Inc. Bispecific multifunctional fusion polypeptide
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
WO2022240159A1 (ko) 2021-05-10 2022-11-17 메디맵바이오 주식회사 항-tigit 항체 및 이의 용도
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
KR20240038043A (ko) * 2021-07-23 2024-03-22 아케소 바이오파마, 인크. 약학적 조성물 및 용도
CN115838424A (zh) * 2021-09-22 2023-03-24 上海康岱生物医药技术股份有限公司 靶向tigit的单克隆抗体
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN116284390A (zh) * 2021-12-21 2023-06-23 广东安普泽生物医药股份有限公司 人tigit抗体及其应用
WO2023149977A1 (en) * 2022-02-04 2023-08-10 Mereo Biopharma 5, Inc. Methods for treating cancer
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
KR20230168598A (ko) * 2022-06-03 2023-12-14 메디맵바이오 주식회사 항-tigit 항체 및 이의 용도
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050809A1 (en) 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
CU23007A1 (es) 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
EP1539228B1 (en) 2002-09-11 2010-12-29 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP2399932B1 (en) 2005-05-12 2016-11-16 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP1945754B1 (en) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2664738C (en) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN104655854A (zh) * 2008-04-09 2015-05-27 健泰科生物技术公司 用于免疫相关疾病的治疗的新组合物和方法
CN102844442B (zh) 2010-02-12 2016-09-07 昂考梅德药品有限公司 用于鉴定和分离表达多肽的细胞的方法
US8785153B2 (en) 2011-02-23 2014-07-22 Hoffmann-La Roche, Inc. Antibodies against human IL33R and uses thereof
SI2925350T1 (sl) 2012-12-03 2019-04-30 Bristol-Myers Squibb Company Izboljšanje protirakave aktivnosti imunomodulatornih FC fuzijskih proteinov
EP2928483A4 (en) 2012-12-04 2016-06-08 Oncomed Pharm Inc IMMUNOTHERAPY BY LIAISON AGENTS
CN103073644B (zh) * 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
US9062104B2 (en) * 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
KR20230118704A (ko) * 2013-07-16 2023-08-11 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을치료하는 방법
RU2690670C2 (ru) 2014-03-12 2019-06-05 Ида Рисерч Энд Дивелопмент Ко., Лтд Снижение уровней или активности системных регуляторных т-клеток для лечения заболевания или повреждения цнс
EP3119913B1 (en) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
AU2015289621A1 (en) 2014-07-16 2017-01-12 Genentech, Inc. Methods of treating cancer using TIGIT inhibitors and anti-cancer agents
UA122395C2 (uk) 2014-08-19 2020-11-10 Мерк Шарп Енд Доум Корп. Антитіло проти tigit
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
BR112017006664A2 (pt) 2014-10-03 2017-12-26 Novartis Ag terapias de combinação
SG11201703376QA (en) 2014-11-06 2017-05-30 Genentech Inc Combination therapy comprising ox40 binding agonists and tigit inhibitors
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
KR102644115B1 (ko) 2014-12-23 2024-03-05 브리스톨-마이어스 스큅 컴퍼니 Tigit에 대한 항체
CN107208138A (zh) 2014-12-30 2017-09-26 豪夫迈·罗氏有限公司 用于癌症预后和治疗的方法和组合物
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3334757A4 (en) 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-TIGIT ANTIBODIES
WO2017037707A1 (en) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
AU2016322934A1 (en) 2015-09-14 2018-04-12 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
RU2732591C2 (ru) 2015-09-25 2020-09-21 Дженентек, Инк. Анти-tigit антитела и способы применения
RU2729379C1 (ru) 2015-10-01 2020-08-06 Потенза Терапевтикс, Инк. Анти-tigit антигенсвязывающие белки и способы их применения
IL261188B (en) 2016-03-04 2022-08-01 Jn Biosciences Llc An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
NZ753515A (en) 2016-11-30 2022-02-25 Oncomed Pharm Inc Methods for treatment of cancer comprising tigit-binding agents

Also Published As

Publication number Publication date
US20160376365A1 (en) 2016-12-29
ECSP17083779A (es) 2018-02-28
IL255577A (en) 2018-01-31
EP3303379A4 (en) 2019-04-17
MX2017014955A (es) 2018-04-13
LT3303379T (lt) 2021-12-10
CO2017012342A2 (es) 2018-02-28
PL3303379T3 (pl) 2022-02-07
RS62815B1 (sr) 2022-02-28
NZ738008A (en) 2019-08-30
JP6875295B2 (ja) 2021-05-19
AU2016267577B2 (en) 2020-12-10
HRP20211948T1 (hr) 2022-03-18
CA2987607A1 (en) 2016-12-01
CN115429877A (zh) 2022-12-06
BR112017025529A2 (pt) 2018-08-07
IL255577B (en) 2022-02-01
MA42622A (fr) 2018-06-20
JP2021118719A (ja) 2021-08-12
CY1125260T1 (el) 2023-03-24
EP4011907A1 (en) 2022-06-15
AU2016267577A1 (en) 2017-12-21
KR20180014050A (ko) 2018-02-07
CL2017003021A1 (es) 2018-06-01
EP3303379B1 (en) 2021-10-13
JP7203446B2 (ja) 2023-01-13
WO2016191643A4 (en) 2017-03-23
PT3303379T (pt) 2022-01-06
TWI715587B (zh) 2021-01-11
HUE057087T2 (hu) 2022-04-28
ES2902150T3 (es) 2022-03-25
US20190077864A1 (en) 2019-03-14
US10544219B2 (en) 2020-01-28
CN109071620B (zh) 2022-05-10
JP2018521634A (ja) 2018-08-09
EP3303379A2 (en) 2018-04-11
SA517390370B1 (ar) 2021-09-12
MD3303379T2 (ro) 2022-02-28
CN109071620A (zh) 2018-12-21
WO2016191643A2 (en) 2016-12-01
US10112997B2 (en) 2018-10-30
SI3303379T1 (sl) 2022-01-31
MA42622B1 (fr) 2021-11-30
TW201718646A (zh) 2017-06-01
WO2016191643A3 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3189081T3 (da) Cd123-bindende midler og anvendelser deraf
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3480213T3 (da) Syntac-polypeptider og anvendelser deraf
DK3265575T3 (da) Cd20-bindende molekyler og anvendelser deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3169741T3 (da) Forbedrede bindemiddelsammensætninger og anvendelser deraf
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3302431T3 (da) Taxanpartikler og anvendelse deraf
DK3310371T3 (da) Glucagon og GLP-1-Co-agonistforbindelser
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3145945T3 (da) Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf